atorvastatin has been researched along with Disease Exacerbation in 154 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.30) | 18.2507 |
| 2000's | 64 (41.56) | 29.6817 |
| 2010's | 81 (52.60) | 24.3611 |
| 2020's | 7 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Arain, HA; Carsons, SE; DeLeon, J; Kasselman, LJ; Petri, M; Reiss, AB; Renna, HA; Voloshyna, I; Zhen, J | 1 |
| Kasahara, M; Kuwabara, Y; Nakao, K; Ueshima, K; Yasuno, S | 1 |
| Bendtsen, F; Deshmukh, AS; Fred, RG; Grønbæk, H; Hansen, T; Kimer, N; Mann, M | 1 |
| Fang, S; Fu, Y; Gu, X; Li, C; Liu, S; Maegdefessel, L; Peng, X; Piao, M; Qian, F; Qin, Z; Qu, W; Sun, C; Sun, Q; Tian, J; Wang, C; Wang, X; Xi, X; Yu, B; Zhang, M; Zhong, S | 1 |
| Dong, J; Liu, J; Wang, J; Wang, Y; Yang, J | 1 |
| Chan, AWH; Chu, ES; Coker, OO; Fu, K; Lau, HCH; Sung, JJY; Wang, YX; Wei, H; Yang, X; Yu, J; Zhang, X | 1 |
| Fullerton, DA; Gergen, AK; Halpern, AL; Kohtz, PD; Meng, X; Weyant, MJ; White, AM | 1 |
| Cicuttini, FM; Ding, C; Forbes, AB; Hill, C; Hussain, SM; Jones, G; Tonkin, A; Wang, Y; Wluka, AE | 1 |
| Baik, SJ; Cho, JH; Choi, IY; Jeong, YJ; Kim, H; Kim, HS; Kim, TM; Lee, H; Lee, SH; Yang, SJ; Yim, HW; Yoon, KH | 1 |
| Arsenault, BJ; Ballantyne, CM; Barter, P; Chapman, MJ; Erbel, R; Hoogeveen, RC; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M | 1 |
| Chen, W; Sun, Z; Tian, T; Wang, S; Xue, Y | 1 |
| Amsterdam, EA; Armstrong, EJ; Choy, HK; Foley, TR; Kokkinidis, DG; Laird, JR; Pham, T; Rutledge, JC; Singh, GD; Waldo, SW | 1 |
| Ahammed, SM; Bishnu, S; Chatterjee, S; Chowdhury, A; Das, K; Dhali, GK; Hembram, J; Sarkar, A | 1 |
| Abreu, L; Antenora, A; Arnoldi, A; Baets, J; Bassi, MT; Bauer, P; Bis, DM; Björkhem, I; Criscuolo, C; De Jonghe, P; Deconinck, T; Filla, A; Fischer, I; Fraidakis, MJ; Hauser, S; Höflinger, P; Jägle, C; Jardim, LB; Klopstock, T; Lourenco, CM; Marques, W; Martinuzzi, A; Martus, P; Meisner, C; Paucar, M; Rattay, TW; Saute, JA; Scarlato, M; Schöls, L; Schüle, R; Smets, K; Stendel, C; Wiethoff, S; Züchner, S | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Barter, P; Boekholdt, SM; Fayyad, R; Hovingh, GK; Kastelein, JJ; Melamed, S; Ray, KK; Vallejo-Vaz, AJ; Waters, DD | 1 |
| Cao, W; Cao, Z; Chen, X; Cheng, J; Gao, W; Guo, S; Jiang, Y; Li, B; Li, M; Li, Q; Li, X; Li, Z; Peng, C; Shen, J; Sun, J; Sun, X; Tian, F; Tian, Y; Tian, Z; Wang, H; Wang, P; Wang, T; Wang, W; Wang, Y; Yang, J; Yang, Y; Yao, J; Zhang, Z; Zhao, X; Zhou, Q | 1 |
| Brescia Morra, V; Carotenuto, A; Chataway, J; Lanzillo, R; Moccia, M; Nozzolillo, A; Palladino, R; Petruzzo, M; Russo, CV | 1 |
| Christodoulou, E; Kadoglou, NPE; Kakisis, J; Kostomitsopoulos, NG; Liapis, CD; Paronis, E; Stasinopoulou, M; Valsami, G | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Lee, CW; Park, SJ | 1 |
| Ding, M; He, W; Jin, J; Wu, H; Xu, M; Yang, X; Yuchi, M | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Baxa, J; Boudová, L; Eberlová, L; Houdek, K; Kobr, J; Kočová, J; Křížková, V; Liška, V; Moláček, J; Nedorost, L; Tolinger, P; Tonar, Z; Třeška, V; Witter, K | 1 |
| Dadjou, Y; Panahi, Y; Pishgoo, B; Rakhshankhah, AS; Sahebkar, A; Taghipour, HR | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Chakrabarti, A; Dhamija, P; Hota, D; Kochhar, R; Sachdev, A | 1 |
| Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H | 1 |
| Amato, AA; Puig, A; Scripko, PD | 1 |
| Coombes, JS; Fassett, RG; Geraghty, DP | 1 |
| Campese, VM | 1 |
| Armstrong, ZB; Boughner, DR; Carruthers, CP; Drangova, M; Rogers, KA | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Adamova, IY; Afanasieva, OI; Balakhonova, TV; Ezhov, MV; Konovalov, GA; Pogorelova, OA; Pokrovsky, SN; Safarova, MS; Tripoten, MI | 1 |
| Cai, X; Ding, J; Li, B; Qian, C; Wang, Y; Wei, B; Wu, H | 1 |
| Agarwal, M; Dash, RP; Ellendula, B; Nivsarkar, M | 1 |
| Akbar, T; Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Looker, HC; Neil, HA | 1 |
| Cicuttini, FM; Ding, C; Forbes, A; Hill, C; Jones, G; Tonkin, A; Wang, Y; Wluka, AE | 1 |
| Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Chen, Z; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Lopez, JJ; Skalicka, H; Sonka, M; Wahle, A; Zhang, L | 1 |
| Cao, JJ; Guerci, A; Pollack, S; Reichek, N; Roth, M; Waheed, S | 1 |
| Cho, L; Elshazly, M; Kapadia, S; King, P; Nicholls, SJ; Nissen, SE; Puri, R; Shao, M; Stegman, B; Tuzcu, M | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Cawley, PJ; Otto, CM | 1 |
| Alber, HF; Bartel, T; Dichtl, W; Feuchtner, GM; Grander, W; Hintringer, F; Müller, S; Pachinger, O; Reinthaler, M; Süssenbacher, A; Ulmer, H | 1 |
| Akgullu, C; Aydinlar, A; Kazazoglu, AR; Ozdemir, B; Yilmaz, Y | 1 |
| Pedersen, TR | 1 |
| Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G | 1 |
| Chen, TY; Kuo, YL; Lin, WC; Tan, TY | 1 |
| Kaburaki, J; Kuwana, M; Okazaki, Y | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Altafullah, I; Birnbaum, G; Cree, B; Morra, VB; Orefice, G; Reder, A; Salvatore, E | 1 |
| Abraham, C; Chalifour, LE; Dostanic, S; Mitmaker, B; Obrand, D; Schweitzer, M; Sheiner, N | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Ferreira, GA; Sato, EI; Teixeira, AL | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Strandberg, TE | 1 |
| Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
| Harward, ML; Jones, MA; Joyce, CJ; Kostner, KM; Kruger, PS; Roberts, MS; Venkatesh, B | 1 |
| Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y; Zhang, X | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS | 1 |
| Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T | 1 |
| Ball, MJ; Cardinal, JW; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Hassanian, MA; Samy, W | 1 |
| Nemati, MH | 1 |
| Bergh, JJ; Mienie, LJ; Terre'Blanche, G; van der Walt, MM | 1 |
| Kiani, AN; Magder, LS; Petri, M; Post, WS | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Brili, S; Hatzis, G; Papageorgiou, N; Stefanadis, C; Tousoulis, D | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K | 1 |
| Bouma, BJ; de Groot, E; Groenink, M; Luijendijk, P; Mulder, BJ; Pieper, PG; Sieswerda, GT; van Dijk, AP; Veen, G; Vliegen, HW; Vriend, JW; Zwinderman, AH | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y | 1 |
| Feig, JE; Fernandez-Hernando, C; Fisher, EA; Garabedian, MJ; Rotllan, N; Shamir, R; Shang, Y; Torra, IP; Vengrenyuk, Y; Wu, C | 1 |
| Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
| Einecke, D | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Brown, K; Bucerius, J; Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Kotsuma, M; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Ramachandran, S; Roytman, M; Rudd, JH; Tanimoto, T; Tsimikas, S; Vucic, E | 1 |
| Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S | 1 |
| Binongo, JN; Corban, MT; Dhawan, SS; Eshtehardi, P; Golub, L; Krishnan, SK; McDaniel, MC; Quyyumi, AA; Raggi, P; Samady, H | 1 |
| Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S | 1 |
| Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X | 1 |
| Barnett, AH; Cooke, MW; Gao, F; Hawkey, P; Hong, T; Jones, A; Linhartova, L; Melody, T; Patel, JM; Perkins, GD; Snaith, C; Thickett, DR | 1 |
| Adamova, IY; Afanasieva, OI; Atanesyan, RV; Ezhov, MV; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS; Utkina, EA | 1 |
| Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Shah, PK | 1 |
| Harman, SM; Hecht, HS | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Nissen, SE | 1 |
| Chang, G; DeNofrio, D; Goldberg, L; Kao, A; Kolansky, DM; Loh, E; Pickering, F; Sasseen, B; See, VY; Wilensky, RL | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Akiba, T; Nihei, H; Nitta, K | 1 |
| Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A | 1 |
| Bhatt, DL; Karha, J | 1 |
| Cheng, X; Cheng, Y; Ge, H; Li, B; Liao, YH; Liu, Y; Lu, B; Wang, M; Yuan, J; Zhang, J | 1 |
| Bloomfield, P; Boon, NA; Cowell, SJ; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Rosenhek, R | 1 |
| Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, MN; Sparks, DL; Wassar, D; Ziolkowski, C | 1 |
| Baller, D; Burchert, W; Gleichmann, U; Horstkotte, D; Pulawski, E; Wielepp, P | 1 |
| Pai, RG | 1 |
| Adamovich, E; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Cairns, T; Cook, HT; Elliot, V | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Boon, NA; Burton, J; Cowell, SJ; Houslay, ES; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Erbel, R; Schmermund, A | 1 |
| Chen, YH; Chua, S; Hang, CL; Hung, WC; Wu, CJ; Yeh, KH; Yip, HK; Youssef, AA | 1 |
| Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA | 1 |
| Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM | 1 |
| Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Canis, M; Hempel, JM; Mazurek, B; Olzowy, B; Suckfüll, M | 1 |
| Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED | 1 |
| Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Amann-Vesti, B; Brockes, C; Koppensteiner, R; Kovacevic, T; Rousson, V; Simon, R; Spring, S; van der Loo, B | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Schlegel, TT; Starc, V; Vrtovec, B | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Asakura, M; Asanuma, H; Kato, H; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Ogai, A; Takashima, S; Zhao, H | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Brown, WV | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Bakker Schut, TC; Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; Römer, TJ; van De Poll, SW; van Der Laarse, A; Volger, OL | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
17 review(s) available for atorvastatin and Disease Exacerbation
| Article | Year |
|---|---|
Association between statin use and incidence or progression of osteoarthritis: meta-analysis of observational studies.
Topics: Atorvastatin; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Observational Studies as Topic; Osteoarthritis; Protective Factors; Risk Factors; Rosuvastatin Calcium | 2020 |
Do statins play a role in renoprotection?
Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Rosuvastatin Calcium; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Prevention of calcific aortic valve stenosis-fact or fiction?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2009 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2010 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2011 |
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Statins and aortic stenosis progression: are biologic targets still an option?
Topics: Aortic Valve Stenosis; Atorvastatin; Disease Progression; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2005 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
68 trial(s) available for atorvastatin and Disease Exacerbation
| Article | Year |
|---|---|
The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperlipidemias; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2020 |
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial.
Topics: Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2020 |
Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial.
Topics: Atorvastatin; Cartilage, Articular; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Osteoarthritis, Knee; Treatment Outcome | 2021 |
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Plaque, Atherosclerotic; Proportional Hazards Models; Rosuvastatin Calcium; Ultrasonography | 2017 |
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atorvastatin; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; India; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Proof of Concept Study; Propranolol; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome | 2018 |
Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Case-Control Studies; Cell Proliferation; Cross-Sectional Studies; Cytochrome P450 Family 7; Disease Progression; Double-Blind Method; Family; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Male; Middle Aged; Mutation; Neurites; Oxysterols; Pedigree; Severity of Illness Index; Spastic Paraplegia, Hereditary; Steroid Hydroxylases; Young Adult | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.
Topics: Adult; Atorvastatin; Disability Evaluation; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Time Factors | 2019 |
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome | 2014 |
Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Disease Progression; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles | 2013 |
Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.
Topics: Acute Disease; Adult; Atorvastatin; Colitis, Ulcerative; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Placebo Effect; Prednisolone; Pyrroles; Severity of Illness Index | 2014 |
Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Immunosorbent Techniques; Lipoprotein(a); Male; Middle Aged; Prospective Studies; Russia; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Up-Regulation | 2015 |
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemoglobin; Humans; Ireland; Male; Middle Aged; United Kingdom | 2016 |
Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Atorvastatin; Australia; Biomechanical Phenomena; Cartilage, Articular; Clinical Protocols; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; Osteoarthritis, Knee; Recovery of Function; Research Design; Time Factors; Treatment Outcome | 2015 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Time Factors; Ultrasonography, Interventional; User-Computer Interface | 2017 |
Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
Topics: Aged; Asymptomatic Diseases; Atorvastatin; Biomarkers; Comorbidity; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Prevalence; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2016 |
Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Sex Factors; Treatment Outcome; Young Adult | 2016 |
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; C-Reactive Protein; Calcinosis; Cholesterol; Disease Progression; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Tomography, X-Ray Computed | 2008 |
Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Elasticity; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors; Vascular Resistance | 2008 |
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography | 2008 |
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index | 2010 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome | 2011 |
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography | 2011 |
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cystatin C; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins; Pyrroles; Young Adult | 2012 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles | 2011 |
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult | 2012 |
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta.
Topics: Adult; Aortic Coarctation; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cytokines; Disease Progression; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Period; Prognosis; Prospective Studies; Pyrroles; Time Factors; Vascular Surgical Procedures | 2012 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effect of two intensive statin regimens on progression of coronary disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2011 |
Rationale and design of a trial on the effect of high dose statins on cardiovascular risk in adults after successful coarctation repair.
Topics: Adult; Aortic Coarctation; Atherosclerosis; Atorvastatin; Cardiac Surgical Procedures; Carotid Arteries; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; History, Ancient; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Care; Prospective Studies; Pyrroles; Treatment Outcome; Ultrasonography | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome | 2013 |
Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Microvessels; Middle Aged; Phenotype; Pilot Projects; Pyrroles; Regional Blood Flow; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional; Vascular Resistance | 2012 |
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial).
Topics: Anti-Inflammatory Agents; Atorvastatin; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome | 2012 |
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Russia; Time Factors; Treatment Outcome | 2013 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Endothelium, Vascular; Female; Heart Transplantation; Heptanoic Acids; Humans; Hyperplasia; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Period; Pyrroles; Tunica Intima | 2003 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Blood Flow Velocity; Calcinosis; Cholesterol, LDL; Disease Progression; Double-Blind Method; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Failure | 2005 |
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cognition; Depression; Disease Progression; Double-Blind Method; Female; Free Radicals; Heptanoic Acids; Humans; Male; Mental Status Schedule; Pilot Projects; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Treatment Outcome; Vasodilation; Ventricular Dysfunction, Left | 2005 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.
Topics: Adult; Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Tomography, Spiral Computed; Treatment Failure | 2006 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Pyrroles; Renal Dialysis; Triglycerides | 2006 |
Effect of torcetrapib on the progression of coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional | 2007 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial.
Topics: Aged; Atorvastatin; Audiometry; Auditory Threshold; Cholesterol; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Hearing Loss, Sensorineural; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Presbycusis; Prospective Studies; Pyrroles; Speech Perception; Tinnitus; Treatment Outcome | 2007 |
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2007 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Topics: Aged; Ankle; Atorvastatin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Arteries; Disease Progression; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Prospective Studies; Pyrroles; Research Design; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
Topics: Atorvastatin; Death, Sudden, Cardiac; Disease Progression; Female; Health Status Indicators; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Risk Factors; Stroke Volume | 2008 |
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors | 2008 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
69 other study(ies) available for atorvastatin and Disease Exacerbation
| Article | Year |
|---|---|
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.
Topics: Adult; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cholesterol; Disease Progression; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Lupus Erythematosus, Systemic; Macrophages; Male; Mixed Function Oxygenases; Plasma; PPAR gamma; RNA, Messenger | 2019 |
Macrophage-Enriched lncRNA RAPIA: A Novel Therapeutic Target for Atherosclerosis.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Proliferation; Disease Progression; Forkhead Box Protein O1; Gene Expression; Humans; Integrin beta1; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; MicroRNAs; Promoter Regions, Genetic; RAW 264.7 Cells; RNA, Long Noncoding | 2020 |
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Case-Control Studies; Cholesterol, Dietary; Disease Progression; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2021 |
Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Animals; Atorvastatin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Random Allocation; Signal Transduction; Simvastatin; Toll-Like Receptor 4; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus; Disease Progression; Electronic Health Records; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Prediabetic State; Quinolines; Republic of Korea; Retrospective Studies | 2017 |
Characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course, and the intervention by statins in very elderly patients.
Topics: Aged; Aged, 80 and over; Atorvastatin; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Male; Treatment Outcome | 2018 |
High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Atorvastatin; Biomarkers; Critical Illness; Disease Progression; Disease-Free Survival; Drug Prescriptions; Dyslipidemias; Endovascular Procedures; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Peripheral Arterial Disease; Practice Patterns, Physicians'; Registries; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Time Factors; Treatment Outcome | 2017 |
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cause of Death; Cholesterol; Cholesterol, LDL; Coronary Disease; Disease Progression; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides | 2018 |
Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Aortic Diseases; Apoptosis; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Peripheral Arterial Disease; Pilot Projects; Plaque, Atherosclerotic; Rabbits; Time Factors; Treatment Outcome; Ultrasonic Therapy | 2019 |
Statins' Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model-A "Rebound" Stimulation of Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Collagen; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Rupture, Spontaneous; Signal Transduction; Time Factors | 2019 |
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Ultrasound common carotid artery segmentation based on active shape model.
Topics: Adventitia; Aged; Algorithms; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Computer Simulation; Disease Progression; Female; Heptanoic Acids; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Anatomic; Pattern Recognition, Automated; Placebos; Pyrroles; Software; Tunica Intima; Tunica Media; Ultrasonography | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Focal histopathological progression of porcine experimental abdominal aortic aneurysm is mitigated by atorvastatin.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Disease Models, Animal; Disease Progression; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Elastase; Pyrroles; Sus scrofa; Time Factors; Ultrasonography | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2014 |
Mystery case: a 63-year-old man with progressive proximal pain and weakness.
Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed | 2014 |
The impact of pre-intervention rate of kidney function change on the assessment of CKD progression.
Topics: Aged; Atorvastatin; Biomarkers; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Recovery of Function; Renal Insufficiency, Chronic; Research Design; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a preclinical model.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Valve; Atorvastatin; Bicuspid Aortic Valve Disease; Disease Progression; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Imidazoles; Immunohistochemistry; Male; Pyrroles; Rabbits; Random Allocation; Sclerosis; Tetrazoles | 2014 |
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction | 2014 |
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein | 2015 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Catechin; Diabetes Mellitus, Experimental; Disease Progression; Ileum; Intestinal Absorption; Male; Rats; Sodium-Potassium-Exchanging ATPase; Verapamil | 2015 |
Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Causality; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Disease Progression; Glucose Intolerance; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Pancreas; Pioglitazone; Postprandial Period; Prediabetic State; Random Allocation; Rats; Rats, Wistar; Thiazolidinediones | 2016 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents | 2008 |
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides | 2009 |
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency | 2009 |
Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cell Count; Cell Separation; Disease Progression; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Flow Cytometry; Fluorescent Antibody Technique; Health Status; Heptanoic Acids; Humans; Immunoprecipitation; Middle Aged; Prospective Studies; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Stem Cells; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Adjuvants, Immunologic; Atorvastatin; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1a; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Pyrroles | 2009 |
Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms.
Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis Regulatory Proteins; Atorvastatin; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Disease Progression; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed | 2011 |
Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia.
Topics: Angioplasty; Atorvastatin; Carotid Stenosis; Disease Progression; Genetic Predisposition to Disease; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver Transplantation; Phenotype; Pyrroles; Radiography; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Treatment Refusal | 2011 |
Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report.
Topics: Adrenoleukodystrophy; Adult; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Erucic Acids; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Pyrroles; Treatment Outcome; Triolein | 2011 |
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Movement; Cholesterol; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Transgenic; Models, Biological; Monocytes; Promoter Regions, Genetic; Pyrroles; Receptors, CCR7; Response Elements; Sterol Regulatory Element Binding Proteins; Sterols | 2011 |
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2011 |
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin.
Topics: Animals; Apolipoproteins B; Atorvastatin; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver X Receptors; Macrophages; Multimodal Imaging; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Rabbits; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study.
Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum | 2013 |
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Calcinosis; Disease Progression; Drug Therapy, Combination; Epichlorohydrin; Heptanoic Acids; Humans; Imidazoles; Prospective Studies; Pyrroles; Renal Dialysis; Resins, Synthetic | 2004 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction.
Topics: Atorvastatin; Cells, Cultured; Disease Progression; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lymphocyte Activation; Male; Middle Aged; Myocardial Infarction; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2005 |
Statins for aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Calcinosis; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Brachytherapy; Disease Progression; Disease-Free Survival; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostatic Neoplasms; Pyrroles | 2005 |
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design | 2006 |
Letter by Schmermund and Erbel regarding article, "Coronary artery calcium: should we rely on this surrogate marker?".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium; Coronary Artery Disease; Coronary Vessels; Disease Progression; Heptanoic Acids; Humans; Predictive Value of Tests; Prognosis; Pyrroles; Risk Factors | 2006 |
Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.
Topics: Angina, Unstable; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Bypass; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Middle Aged; Nephelometry and Turbidimetry; Prognosis; Pyrroles; Retrospective Studies; Severity of Illness Index; Stents; Time Factors; von Willebrand Factor | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis | 2007 |
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2007 |
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus | 2007 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Topics: Animals; Atorvastatin; Cardiomegaly; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Heart Failure; Heparin-binding EGF-like Growth Factor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation; Pyrroles; Ventricular Function, Left | 2008 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcinosis; Cholesterol; Diet, Atherogenic; Disease Progression; Female; Heptanoic Acids; Male; Mice; Mice, Transgenic; Pyrroles; Reproducibility of Results; Spectrum Analysis, Raman; Treatment Outcome | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |